Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy

NCT00418574 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT00418574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00418574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy
Lead sponsor
Menarini Group
Phase
Phase 2/3
Overall status
Terminated
Start date
December 31, 2006
Completion date
June 30, 2011
Enrollment
888 (actual)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer